Join Growin Stock Community!

Relmada therapeutics, inc.RLMD.US Overview

US StockHealthcare
(No presentation for RLMD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RLMD AI Insights

RLMD Overall Performance

RLMD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RLMD Recent Performance

6.36%

Relmada therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

RLMD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RLMD Key Information

RLMD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RLMD Profile

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Price of RLMD

RLMD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RLMD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.77
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
35.56
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.77
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
35.56
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is RLMD's latest earnings report released?

    The most recent financial report for Relmada therapeutics, inc. (RLMD) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RLMD's short-term business performance and financial health. For the latest updates on RLMD's earnings releases, visit this page regularly.

  • How much cash does RLMD have?

    At the end of the period, Relmada therapeutics, inc. (RLMD) held Total Cash and Cash Equivalents of 1.38M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is RLMD's EPS continuing to grow?

    According to the past four quarterly reports, Relmada therapeutics, inc. (RLMD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.3. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RLMD?

    Relmada therapeutics, inc. (RLMD)'s Free Cash Flow (FCF) for the period is -6.72M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 59.64% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.